VC-Backed IPO Market 2026: 992 Unicorns Wait as Q3 Listings Lean on Biotech

PitchBook counts a record 992 unicorns, but only 18 US venture-backed companies listed in the third quarter, most of them in healthcare. Rate hikes, high bond yields and the coming AI mega-listings are shaping the queue founders are standing in.

There have never been so many startups worth $1 billion or more, and very few of them are going public. PitchBook’s third-quarter Venture Monitor, released October 8, counted a record 992 unicorns with a combined value of $5.7 trillion. In the same quarter, the VC-backed IPO count was 18, and healthcare accounted for 12 of them.

Where it stands: Crunchbase, which counts North America rather than the US alone, found 17 venture-backed companies going public on major US and Canadian exchanges in Q3, raising just under $4 billion between them. The two biggest names in the queue, Anthropic and OpenAI, had not listed by mid-October.

Founders who expected 2026 to reopen the public markets for everyone have seen something narrower: a window that admits a few biotech companies, a handful of AI infrastructure deals and, soon, the AI labs themselves.

The VC-backed IPO count in Q3: small, and mostly biotech

PitchBook’s description of the quarter’s listings, as reported by SiliconANGLE, was “rather mundane.” Of the 18 venture-backed companies that went public, 12 were in healthcare, “and none was an AI company of the sort Tarhuni said the market needs for liquidity.” Nizar Tarhuni, PitchBook’s executive vice president of research, said “the real story sits on the exit side.”

Renaissance Capital’s quarterly review, covering all US IPOs and not just venture-backed ones, found 30 listings raising $32.8 billion. Almost all of that came from one deal: without Korea’s SK hynix, proceeds were $6.2 billion. The third-quarter average over the past decade is 49 IPOs raising $12.1 billion, by Renaissance’s count.

Biotech carried the quarter’s deal count. Renaissance says healthcare “produced nine IPOs, all biotechs, that raised a combined $2.4 billion.”

Why the window stayed narrow

Renaissance’s explanation, in its own words: “IPO activity came in below expectations in the third quarter of 2026, as more concerns about AI spending, a 19-year high in bond yields, and resumed rate hikes weighed on the fall pickup.” The expected September rebound turned instead into “a string of postponements and a high-profile delay from SB Energy.”

The rate pressure was building before the fall. The Federal Reserve’s May Financial Stability Report observed that 2- and 10-year Treasury yields “continued to be well above their average levels over the past 15 years,” and market contacts in its survey warned that a correction in risk assets could be triggered by “aI valuation concerns.” That is the backdrop Renaissance describes: a growth company pricing an IPO this fall faced bond yields at a 19-year high and investors already uneasy about AI valuations.

The AI giants at the front of the queue

The listings everyone is waiting for are the AI labs. Crunchbase reported that Anthropic was “reportedly eyeing a public list as early as November,” while OpenAI “filed confidentially for an IPO in June and is expected to make its debut in 2027.” On PitchBook’s exit model, the odds of Anthropic listing within twelve months are 86%, against 12% for OpenAI. (Our explainer on confidential IPO filings covers what that process does and doesn’t reveal.)

Renaissance flags a side effect that fits the oxygen argument. Its review lists recent market moves, the midterm elections “and Anthropic’s expected mega IPO” as factors that “complicate the end-of-year timeline.” That is Renaissance’s reading of the calendar, not a measured effect. It echoes what founders have seen in private funding this year, where a few very large AI rounds dominated the totals.

Where the exits went instead

With few listings, acquisitions did the work, and one deal dominated. SpaceX’s $60 billion all-stock purchase of Anysphere, the company behind Cursor, “accounted for 53.1% of third-quarter exit value on its own,” per the PitchBook report. Without it, the quarter’s exits come to $53 billion, which PitchBook says would be the lowest since late 2024.

Prices on many of those exits were well below the last private round. Bending Spoons bought Airtable for $1.3 billion, against an $11.7 billion valuation. On Forge Global’s secondary market, shares in startups whose last round was in 2021 change hands at a median discount of 59%, PitchBook reported.

Louis Lehot of Foley & Lardner, writing on PitchBook’s August fundraising and returns report, highlighted the capital it takes to get to a big exit: “The median company exiting above $500 million has raised $323.7 million to get there.” A decade earlier it was $157 million, he notes, “and exit sizes have barely moved since.” The step-up at exit, by his account, “collapsed from 62.8% in 2021 to 15.5% today.” Employees holding options in a richly valued company face the same math, as our piece on why a funding round is not a cash exit explains.

The counter-evidence: the window is open, just not wide

This is not a closed market. PitchBook notes that 2026’s listings through September already outnumber the full-year total of each of the three prior years, though it called that “a low bar to cross.” Renaissance found that “the third quarter brought greater breadth to the IPO market, showing renewed appetite for stories beyond AI and biotech,” with consumer and financial issuers returning.

Biotech listings also traded reasonably: “The healthcare sector averaged a return of 17%, driven by decent trading from the quarter’s biotech IPOs,” per Renaissance’s returns data through September 30.

Measure (Q3 2026) Figure Counted by
US venture-backed IPOs 18 (12 healthcare) PitchBook-NVCA
North American venture-backed IPOs 17, just under $4B raised Crunchbase
All US IPOs 30, $32.8B ($6.2B ex-SK hynix) Renaissance Capital
Unicorns, end of September 992 PitchBook-NVCA
Anthropic IPO odds within a year 86% PitchBook exit model

The counts differ because the definitions do: PitchBook counts US venture-backed listings, Crunchbase counts the US and Canada, and Renaissance counts all US IPOs above its size cutoff.

What founders can read from the queue

The numbers describe a private market that has grown faster than its exits. PitchBook says “The 179 new unicorns minted this year outnumber the IPOs of any year but 2021.” Tarhuni’s view is that the IPO pipeline keeps slipping further out, leaving sellers to rely on M&A “to get anything done at all.”

Some in the industry think the change is permanent. PitchBook’s Kyle Stanford told Fortune in June: “I don’t see a change where IPOs again become the goal of companies.” The funds that need those exits are themselves concentrated, which our look at VC fundraising concentration lays out.

For a founder planning an exit, the data points to acquisitions and secondary sales as the more common routes in 2026, at prices that often sit below the last round. Even the alternative to an IPO struggled: Renaissance says seven companies chose a direct listing in Q3, the most in any quarter on record, and only one of them finished the quarter above its opening price.

Frequently Asked Questions

How many VC-backed companies went public in Q3 2026?

It depends on who is counting. PitchBook-NVCA counted 18 US venture-backed IPOs, 12 of them in healthcare. Crunchbase counted 17 venture-backed North American companies listing on major US and Canadian exchanges, raising just under $4 billion together.

How many unicorns are waiting to go public?

PitchBook counted a record 992 startups valued at $1 billion or more at the end of September 2026, with a combined value of $5.7 trillion.

Why was the IPO market slow in fall 2026?

Renaissance Capital pointed to worries over AI spending, bond yields at a 19-year high and the return of rate hikes, which together produced a string of postponements near the end of the third quarter.

When will Anthropic and OpenAI go public?

Neither had listed as of mid-October 2026. Crunchbase reported that Anthropic was reportedly eyeing a listing as early as November and that OpenAI had filed confidentially and is expected to debut in 2027. PitchBook’s exit model put the odds of Anthropic listing within twelve months at 86%, against 12% for OpenAI.

Are non-AI companies still able to IPO?

Yes. Most of the third quarter’s venture-backed listings were healthcare companies, and Renaissance Capital said the quarter showed renewed appetite for stories beyond AI and biotech.

Sources

This article is general information for founders and is not legal, accounting or investment advice. Funding and market figures are as reported by the sources cited on the dates shown and can change.